Latest Content

New initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo in adults with narcolepsy type 1 and type 2.

Explore fresh clinical insights on schizophrenia—mortality, stigma, cannabis links, lifestyle, and new treatments—and share cases for our April series.

Q1 psychiatric pipeline shifts: wins, setbacks, and standout trials in depression, schizophrenia, Alzheimer disease, and narcolepsy—what to watch next.

How will AI influence psychiatry training?

Being a fool can run from being thought to be inappropriately silly to Shakespeare’s fools of creative wisdom. Where does psychiatry come in?

Elite coaches often run on severe sleep loss, risking impaired decisions, emotion control, and leadership.

Continuity vs discontinuity, tradition vs change in the “psy disciplines.”

Check out the pipeline updates from March!

Further data shared on LB-102 for schizophrenia.

Tazbentetol interim results show improvement in schizophrenia symptoms.

ASAM announces new youth substance use disorder criteria, promoting early intervention, family-focused care, integrated mental health, and updated levels of treatment.

Why men struggle in silence: suicide risks, hidden depression signs, and practical ways therapy and connection help.

How medical conferences cut carbon footprint: greener travel, water stations, compostables, recycled badges, and offsets—AAP’s 2025 model.